May 2019
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This seminar was a timely opportunity to discuss the future for the regulation of medicines, clinical trials and medical devices in the UK.
Attendees discussed what more could be done to ensure that the regulatory process supports the development of new treatments within the UK - in light of the publication of the NHS Long Term Plan and additional investment in the Life Sciences Sector Deal 2, which set out sector and government actions to promote innovative regulation.
The seminar followed the Department of Health and Social Care’s announcement that the Accelerated Access Collaborative (AAC) will become a new organisation for innovation to speed up the uptake of pioneering treatments.
There was discussion on the role of the AAC in quickening the pace of the regulatory approval process for proven innovations - as well as what further support could be provided to innovators.
Delegates assessed the changing landscape of healthcare regulation and the future role of the UK in European regulatory procedures - including key issues for maintaining access, innovation and the supply of medicines to the UK.
Sessions focused on priorities for the Health Research Authority as it develops a new strategy for clinical trials transparency, ahead of the expected publication later this year - such as if further funding will be needed, how improvements in transparency will be measured and how non-compliance with transparency regulations should be responded to.
